MediWound Reports Second Quarter 2022 Financial Results and Provides Company Updates
August 09, 2022 07:30 ET
|
MediWound Ltd.
Positive Results in Two Phase 2 Trials of EscharEx FDA Assigned PDUFA Target Date of January 1, 2023 for NexoBrid BLA Enhanced the Board and Leadership Team Conference Call Begins Today at 8:30 AM...
MediWound Enhances Its Board and Executive Leadership Team
August 08, 2022 16:05 ET
|
MediWound Ltd.
Mr. Nachum Shamir appointed as Chairman of the Board Dr. Robert Snyder appointed as Chief Medical Officer YAVNE, Israel, Aug. 08, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the...
MediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
August 03, 2022 07:30 ET
|
MediWound Ltd.
YAVNE, Israel, Aug. 03, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for...
MediWound Schedules Second Quarter 2022 Financial Results
August 01, 2022 08:00 ET
|
MediWound Ltd.
Call Scheduled for Tuesday, August 9, 2022 at 8:30 AM Eastern Time YAVNE, Israel, Aug. 01, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company...
MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
July 11, 2022 07:00 ET
|
MediWound Ltd.
MW005 Shown to Be Safe and Well-ToleratedTarget Lesions Clearance Data Provides Clinical Efficacy Proof-of-Concept YAVNE, Israel, July 11, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD)...
MediWound Announces Presentation on EscharEx at the Advanced Wound Care Summit in Boston on July 13
July 08, 2022 08:00 ET
|
MediWound Ltd.
YAVNE, Israel, July 08, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...
MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers
July 07, 2022 07:00 ET
|
MediWound Ltd.
EscharEx Showed Safe, Effective and Rapid Debridement in VLUs and DFUsData Demonstrates EscharEx Reduced Wound Size, Biofilm and Bacterial Burden YAVNE, Israel, July 07, 2022 (GLOBE NEWSWIRE) --...
MediWound to Host a Key Opinion Leader Investor Day on EscharEx
July 05, 2022 16:05 ET
|
MediWound Ltd.
YAVNE, Israel, July 05, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...
MediWound Names Mr. Tzvi Palash as Chief Operating Officer
June 30, 2022 07:00 ET
|
MediWound Ltd.
YAVNE, Israel, June 30, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...
MediWound Announces CEO Transition
May 17, 2022 07:01 ET
|
MediWound Ltd.
Ofer Gonen, current Board member and CEO of Clal Biotechnology Industries Ltd., appointed as New CEO – Effective June 30 Will replace current CEO Sharon Malka, who will join the Board of Directors ...